Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
The expected taxonomic range for this enzyme is: Human T-cell leukemia virus type I
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(((4-((4-dimethylamino)phenyl)azo)phenyl)sulfonyl)amino-(gamma-aminobutyric acid)-PQVL-F(NO2)-VMH-(5-(2-aminoethylamino)-1-naphthalenesulfonic acid) + H2O
(((4-((4-dimethylamino)phenyl)azo)phenyl)sulfonyl)amino-(gamma-aminobutyric acid)-PQVL + F(NO2)-VMH-(5-(2-aminoethylamino)-1-naphthalenesulfonic acid)
-
-
-
?
(((4-((4-dimethylamino)phenyl)azo)phenyl)sulfonyl)amino-(gamma-aminobutyric acid)-PQVL-PVMH-(5-(2-aminoethylamino)-1-naphthalenesulfonic acid) + H2O
(((4-((4-dimethylamino)phenyl)azo)phenyl)sulfonyl)amino-(gamma-aminobutyric acid)-PQVL + PVMH-(5-(2-aminoethylamino)-1-naphthalenesulfonic acid)
-
-
-
?
4-((4-dimethylaminophenylazo)benzoyl)-(gamma-aminobutyric acid)-PQVL-(4-nitro)Phe-VMH-(5-(2-aminoethylamino)-1-naphthalenesulfonic acid) + H2O
?
-
-
-
-
?
Ac-Ala-Pro-Gln-Val-Sta-Val-Met-His-Pro
?
Ac-DALLITPVLQLSPAF-OH + H2O
Ac-DALLITPVLQL-OH + SPAF-OH
-
peptide corresponding to the amino acids ranging from Asp1157 to Ala1169 of the pol open reading frame of HTLV-I
-
?
Ac-KDKT-(N-o-aminobenzoyl)KVL-(4-nitro)FVQPKK-NH2 + H2O
Ac-KDKT-(N-o-aminobenzoyl)KVL + (4-nitro)FVQPKK-NH2
-
fluorogenic substrate
-
-
?
Ace-Pro-Val-Ile-Leu-Pro-Ile-NMe + H2O
Ace-Pro-Val-Ile-Leu + Pro-Ile-NMe
-
-
-
?
Ala-Pro-Gln-Val-Leu-Phe(4-NO2)-Val-Met-His-Pro-Leu + H2O
Ala-Pro-Gln-Val-Leu + Phe(4-NO2)-Val-Met-His-Pro-Leu
-
substrate mimicks the natural Gag-Pol cleavage site of HTLV-1
-
-
?
Ala-Pro-Gln-Val-Sta-Val-Met-His-Pro-Leu + H2O
?
-
-
-
-
?
APQVLF(NO2)VMHPL + H2O
?
-
-
-
-
?
APQVLF(NO2)VMHPL + H2O
APQVL + F(NO2)VMHP
-
-
-
-
?
APQVLNphVMHPL + H2O
?
-
-
-
-
?
APQVLPVMHP + H2O
APQVL + PVMHP
APQVLPVMHPHG + H2O
APQVL + PVMHPHG
dabsyl-(GABA)-PQVLPVMH-EDANS + H2O
dabsyl-(GABA)-PQVL + PVMH-EDANS
-
fluorogenic peptide substrate containing a MA/CA cleavage site
-
-
?
dabsyl-KTKVLVVQPK-EDANS + H2O
dabsyl-KTKVL + VVQPK-EDANS
-
i.e. peptide substrate IB268, fluorescent-labeled
-
-
?
DELILPVKRK + H2O
DELIL + PVKRK
-
-
-
-
?
DKELYPLTSL + H2O
DKELY + PLTSL
-
low activity
-
-
?
DPASILPVIP + H2O
DPASIL + PVIP
eukaryotic initiation factor eIF4GI + H2O
?
HTLV-1 Gag + H2O
?
-
processing of the HTLV-1 Gag protein
-
-
?
IPFAAAQQRK + H2O
IPFAA + AQQRK
-
-
-
-
?
IQPLIMAVVNR + H2O
IQPLIM + AVVNR
-
good substrate
-
-
?
IRKILFLDG + H2O
IRKIL + FLDG
-
-
-
-
?
IRQVLFLEKI + H2O
IRQVL + FLEKI
-
good substrate
-
-
?
KAKVLVVQPK + H2O
KAKVL + VVQPK
-
-
-
?
KDKVLVVQPK + H2O
KDKVL + VVQPK
-
-
-
?
KGKVLVVQPK + H2O
KGKVL + VVQPK
-
-
-
-
?
KGPPVICPIQA + H2O
KGPPVIC + PIQA
-
the preferred amino acids at the P1 position, except for Leu, are hydrophobic Phe and sulfur-containing amino acids (Met and Cys). Substrates which contain a charged side chain at the P1 position are not cleaved
-
-
?
KGPPVIFPIQA + H2O
KGPPVIF + PIQA
-
the preferred amino acids at the P1 position, except for Leu, are hydrophobic Phe and sulfur-containing amino acids (Met and Cys). Substrates which contain a charged side chain at the P1 position are not cleaved
-
-
?
KGPPVILPIQA + H2O
KGPPVIL + PIQA
-
Pro residue at the P1' position is the preferred amino acid for hydrolysis, and no replacement at the P1' position seems to be tolerated
-
-
?
KGPPVILPIQAP + H2O
?
-
12-residue standard peptide, 100% cleavage
-
-
?
KGPPVILPIQAP + H2O
KGPPVIL + PIQAP
KGPPVIMPIQA + H2O
KGPPVIM + PIQA
-
the preferred amino acids at the P1 position, except for Leu, are hydrophobic Phe and sulfur-containing amino acids (Met and Cys). Substrates which contain a charged side chain at the P1 position are not cleaved
-
-
?
KGVKVLVVQPK + H2O
KGKVL + VVQPK
-
-
-
?
KLKVLVVQPK + H2O
KLKVL + VVQPK
-
-
-
?
KPVKVLVVQPK + H2O
KPKVL + VVQPK
-
-
-
?
KQPAILVHTPG + H2O
KQPAIL + VHTPG
-
-
-
?
KSKVLVVQPK + H2O
KSKVL + VVQPK
-
-
-
?
KTAVLVVQPK + H2O
KTAVL + VVQPK
-
-
-
?
KTDVLVVQPK + H2O
KTDVL + VVQPK
-
-
-
?
KTFVLVVQPK + H2O
KTFVL + VVQPK
-
-
-
?
KTGVLVVQPK + H2O
KTGVL + VVQPK
-
-
-
?
KTKFLVVQPK + H2O
KTKFL + VVQPK
-
-
-
?
KTKILVVQPK + H2O
KTKIL + VVQPK
-
-
-
?
KTKLLVVQPK + H2O
KTKLL + VVQPK
-
-
-
?
KTKVAVVQPK + H2O
KTKVA + VVQPK
-
-
-
?
KTKVFVVQPK + H2O
KTKVF + VVQPK
-
-
-
?
KTKVGFVQPK + H2O
KTKVG + FVQPK
-
-
-
?
KTKVGIVQPK + H2O
KTKVG + IVQPK
-
-
-
?
KTKVGVVQPK + H2O
KTKVG + VVQPK
-
-
-
?
KTKVLFVQPK + H2O
KTKVL + FVQPK
-
-
-
-
?
KTKVLIVQPK + H2O
KTKVL + IVQPK
-
-
-
-
?
KTKVLLVQPK + H2O
KTKVL + LVQPK
-
-
-
?
KTKVLVVQPK + H2O
KTKVL + VVQPK
KTKVMGVVQPK + H2O
KTKVM + VVQPK
-
-
-
?
KTKVMVVQPK + H2O
KTKVM + VVQPK
-
-
-
-
?
KTKVYVVQPK + H2O
KTKVY + VVQPK
-
-
-
?
KTLVLVVQPK + H2O
KTLVL + VVQPK
-
-
-
?
KTSVLVVQPK + H2O
KTSVL + VVQPK
-
-
-
?
KTVVLVVQPK + H2O
KTVVL + VVQPK
-
-
-
?
KVKVLVVQPK + H2O
KVKVL + VVQPK
-
-
-
?
LTFTFPVVFMRR + H2O
LTFTF + PVVFMRR
-
low activity
-
-
?
N6-(7-methoxycoumarin-4-yl)acetyl-L-Lys-L-Ala-L-Pro-L-Gln-L-Val-L-Leu-4-nitro-L-phenylalanine-L-Val-L-Met-L-His-L-Pro-L-Leu + H2O
L-Lys-(7-methoxycoumarin-4-yl)acetyl-L-Ala-L-Pro-L-Gln-L-Val-L-Leu + 4-nitro-L-phenylalanine-L-Val-L-Met-L-His-L-Pro-L-Leu
-
-
-
-
?
PKDIFPVTET + H2O
PKDIF + PVTET
-
-
-
-
?
PLQVLTLNIERR + H2O
PLQVL + TLNIERR
-
-
-
-
?
PPAILPIISE + H2O
PPAIL + PIISE
PPMVGVLDAP + H2O
PPMVG + VLDAP
-
-
-
-
?
PPVILPIQ + H2O
?
-
-
-
-
?
PPVILPIQA + H2O
?
-
a 9-residue peptide is cleaved approximately at 85% of the 12-residue standard peptide
-
-
?
PPVILPIQAP + H2O
?
-
-
-
-
?
PPVMGVLDAP + H2O
PPVMG + VLDAP
-
-
-
?
PQVLPVMHP + H2O
PQVL + PVMHP
PVILPIQ + H2O
?
-
minimal sequence required for substrate recognition is a 7-residue peptide
-
-
?
PVILPIQA + H2O
?
-
-
-
-
?
PVILPIQAP + H2O
?
-
-
-
-
?
PVVAMPVVIK + H2O
PVVAM + PVVIK
-
-
-
-
?
RATVLTVALH + H2O
RATVL + TVALH
-
-
-
-
?
TKVLVVQPK + H2O
TKVL + VVQPK
VLQLYPIVQ + H2O
VLQLY + PIVQ
-
-
-
?
VMQIYPIVQ + H2O
VMQIY + PIVQ
-
-
-
?
VSQCYPIVG + H2O
VSQCY + PIVG
-
peptides with an Ile or Leu at position P2 are the best substrate, lower activity with Val or Cys at position P2, no activity with Ala, Phe, Gly Thr or An at position P2
-
-
?
VSQIYPIVG + H2O
VSQIY + PIVG
-
peptides with an Ile or Leu at position P2 are the best substrate, lower activity with Val or Cys at position P2, no activity with Ala, Phe, Gly Thr or An at position P2
-
-
?
VSQIYPIVQ + H2O
VSQIY + PIVQ
-
-
-
-
?
VSQLYPIVG + H2O
VSQLY + PIVG
-
peptides with an Ile or Leu at position P2 are the best substrate, lower activity with Val or Cys at position P2, no activity with Ala, Phe, Gly Thr or An at position P2
-
-
?
VSQLYPIVQ + H2O
VSQLY + PIVQ
-
-
-
-
?
VSQNYPIVQ + H2O
VSQNY + PIVQ
-
-
-
?
VSQVYPIVG + H2O
VSQVY + PIVG
-
peptides with an Ile or Leu at position P2 are the best substrate, lower activity with Val or Cys at position P2, no activity with Ala, Phe, Gly Thr or An at position P2
-
-
?
VSQVYPIVQ + H2O
VSQVY + PIVQ
-
-
-
?
YVEPTAPQVLPVMHP + H2O
?
-
-
-
-
?
additional information
?
-
Ac-Ala-Pro-Gln-Val-Sta-Val-Met-His-Pro
?
substrate analogue, based on the natural MA/CA cleavage site of HTLV-I protease
-
-
?
Ac-Ala-Pro-Gln-Val-Sta-Val-Met-His-Pro
?
Human T-cell leukemia virus type I Japan ATK-1 subtype A
substrate analogue, based on the natural MA/CA cleavage site of HTLV-I protease
-
-
?
APQVLPVMHP + H2O
APQVL + PVMHP
-
-
-
-
?
APQVLPVMHP + H2O
APQVL + PVMHP
-
-
-
?
APQVLPVMHP + H2O
APQVL + PVMHP
-
-
-
-
?
APQVLPVMHPHG + H2O
APQVL + PVMHPHG
-
-
-
-
?
APQVLPVMHPHG + H2O
APQVL + PVMHPHG
-
-
-
?
APQVLPVMHPHG + H2O
APQVL + PVMHPHG
-
-
-
-
?
DPASILPVIP + H2O
DPASIL + PVIP
-
-
-
-
?
DPASILPVIP + H2O
DPASIL + PVIP
-
-
-
?
DPASILPVIP + H2O
DPASIL + PVIP
-
-
-
-
?
eukaryotic initiation factor eIF4GI + H2O
?
-
-
-
-
?
eukaryotic initiation factor eIF4GI + H2O
?
-
in transfected COS-7 cells
-
-
?
gag precursor + H2O
?
-
-
-
-
?
gag precursor + H2O
?
-
HRTV-1 gag precursor polyprotein
-
-
?
gag precursor + H2O
?
-
HTVL-1 Gag
-
-
?
KGPPVILPIQAP + H2O
KGPPVIL + PIQAP
-
-
-
?
KGPPVILPIQAP + H2O
KGPPVIL + PIQAP
-
-
-
?
KGPPVILPIQAP + H2O
KGPPVIL + PIQAP
-
-
-
-
?
KTKVLVVQPK + H2O
KTKVL + VVQPK
-
-
-
-
?
KTKVLVVQPK + H2O
KTKVL + VVQPK
-
-
-
?
KTKVLVVQPK + H2O
KTKVL + VVQPK
-
-
-
-
?
KTKVLVVQPK + H2O
KTKVL + VVQPK
-
i.e. peptide substrate IB268, good substrate
-
-
?
PPAILPIISE + H2O
PPAIL + PIISE
-
-
-
?
PPAILPIISE + H2O
PPAIL + PIISE
-
good substrate
-
-
?
PQVLPVMHP + H2O
PQVL + PVMHP
-
-
-
?
PQVLPVMHP + H2O
PQVL + PVMHP
-
-
-
-
?
TKVLVVQPK + H2O
TKVL + VVQPK
-
-
-
?
TKVLVVQPK + H2O
TKVL + VVQPK
-
-
-
-
?
additional information
?
-
-
the substrate binding site of HTLV-I protease is different from the substrate binding sites of pspsin and HIV-1 protease
-
-
?
additional information
?
-
-
the original HIV-1 matrix/capsid cleavage site substrate and most of its substituted peptides are not hydrolyzed by the HTLV-1 enzyme
-
-
?
additional information
?
-
-
the active site of the HTLV-1 protease may have subtle differences in substrate recognition compared with the HIV-1 protease
-
-
?
additional information
?
-
-
the enzyme produces the mature strucrtural proteins and enzymes essential for viral replication
-
-
?
additional information
?
-
-
the cleavage site between the capsid and the nucleocapsid protein of HTLV-1 is evolutionary optimized for rapid hydrolysis
-
-
?
additional information
?
-
-
no cleavage of poly(A)-binding protein in transfected COS-7 cells
-
-
?
additional information
?
-
-
no cleavage of poly(A)-binding protein
-
-
?
additional information
?
-
-
specificity of wild-type and mutant HTLV-1 PRs with diverse cleavage sites, overview
-
-
?
additional information
?
-
-
the 10 C-terminal residues of HTLV-I protease are not necessary for enzymatic activity
-
-
?
additional information
?
-
-
no cleavage using substrates: VILPIQAP, VILPIQA, VILPIQ, PPVILPI, PVILPI
-
-
?
additional information
?
-
-
preference for Pro at the P1' position and for Ile at the P2 position. Hydrophobic Phe and Gln residues are acceptable in the P3 position and a Gln residue at the P4 position
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2R)-2-[(3-[[(R)-amino(hydroxy)methyl][2-hydroxy-2-(naphthalen-2-yl)ethyl]amino]-3-cyclopentylpropyl)amino]-N-benzyl-2-hydroxyethanesulfonamide
-
-
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-(2,2-dimethyl)butanoylamino-2-phenyl]acetylamino-3,3-dimethyl)-butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-(2-methyl)pentanoylamino-2-phenyl]acetylamino-3,3-dimethyl)- butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-(3,3-dimethyl)butanoylamino-2-phenyl]acetylamino-3,3-dimethyl)-butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-(3-methyl)butanoylamino-2-phenyl]acetylamino-3,3-dimethyl)-butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-(3-methyl)pentanoylamino-2-phenyl]acetylamino-3,3-dimethyl)butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-(3-phenyl)-propanoylamino-2-phenyl]acetylamino-3,3-dimethyl)butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-(4-methyl)pentanoylamino-2-phenyl]acetylamino-3,3-dimethyl) butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-acetylamino-2-phenyl]acetylamino-3,3-dimethyl)butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-amino-2-phenyl]acetylamino-3,3-dimethyl)butanoylamino-2-hydroxy-4-phenylbutanoyl))-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-benzoylamino-2-phenyl]acetylamino-3,3-dimethyl)butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-cyclohexanecarbonylamino-2-phenyl]acetylamino-3,3-dimethyl)-butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-isobutyrylamino-2-phenyl]acetylamino-3,3-dimethyl)butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-pentanoylamino-2-phenyl]acetylamino-3,3-dimethyl)butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-propionylamino-2-phenyl]acetylamino-3,3-dimethyl)butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(R)-N-isobutyl-3-[[(2S,3S)-3-[(2S)-2-[(2S)-2-butyrylamino-2-phenyl]acetylamino-3,3-dimethyl]butanoylamino-2-hydroxy-4-phenyl]]butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(R)-N-isobutyl-3-[[(2S,3S)-3-[(2S)-2-[(2S)-2-cyclopropanecarbonylamino-2-phenyl]acetylamino-3,3-dimethyl]butanoylamino-2-hydroxy-4-phenyl]]butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(R)-N-Isobutyl-3-[[(2S,3S)-3-[(2S)-2-[(2S)-2-pivaloylamino-2-phenyl]acetylamino-3,3-dimethyl]butanoylamino-2-hydroxy-4-phenyl]]butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
2-(4-tert-butylphenyl)-N-carbamoyl-N-[3-([[(pyridin-1(2H)-ylmethyl)sulfamoyl]carbonyl]amino)-3-(pyrrolidin-1-yl)propyl]acetamide
-
-
-
2-(4-tert-butylphenyl)-N-carbamoyl-N-[3-[([[(3,5-dichloro-4-oxopyridin-1(4H)-yl)methyl]sulfamoyl]carbonyl)amino]-3-[3-(hydroxyamino)-4-oxopyrrolidin-1-yl]propyl]acetamide
-
4-[(anilinocarbonyl)amino]-6-chlorobenzene-1,3-disulfonamide
-
-
Ac-Ala-Pro-Gln-Val-Sta-Val-Met-His-Pro
-
19% inhibition at 50 nM
Ac-Ala-Pro-Gln-Val-statine-Val-Met-His-Pro
-
binding mode in an extended conformation at the active site, competitive, binding-involved residues of the S2/S2'-subsite, overview
Ac-Ala-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Val-Met-NH2
-
HTLV-I inhibition 56%
Ac-allophenylnorstatine-Pro-Val-Met-His-OH
-
HTLV-I inhibition below 30%
Ac-Gln-(R)-S-methyl-L-cysteine-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Val-Met-NH2
-
HTLV-I inhibition 51%
Ac-Gln-Ile-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Val-Met-NH2
-
HTLV-I inhibition 85%
Ac-Gln-Leu-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Val-Met-NH2
-
HTLV-I inhibition 54%
Ac-Gln-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid- (R)-S-methyl-L-Cys-Met-NH2
-
HTLV-I inhibition below 30%
Ac-Gln-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Ile-Met-NH2
-
HTLV-I inhibition 74%
Ac-Gln-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Leu-Met-NH2
-
HTLV-I inhibition 30%
Ac-Gln-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Thr-Met-NH2
-
HTLV-I inhibition below 30%
Ac-Gln-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Val-Met-NH2
-
HTLV-I inhibition 66%; HTLV-I inhibition 99%
Ac-Gln-Val-allophenylnorstatine-Pro-Val-Met-His-OH
-
HTLV-I inhibition 49%
Ac-Ile-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Ile-Met-NH2
-
HTLV-I inhibition 94%
Ac-Ile-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Val-Gln-NH2
-
HTLV-I inhibition 86%
Ac-Ile-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Val-Ile-NH2
-
HTLV-I inhibition 78%
Ac-Ile-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Val-Leu-NH2
-
HTLV-I inhibition 54%
Ac-Ile-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Val-Met-NH2
-
HTLV-I inhibition 87%
Ac-Ile-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Val-Phe-NH2
-
HTLV-I inhibition 84%
Ac-Ile-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Val-Val-NH2
-
HTLV-I inhibition 70%
Ac-Leu-Lys-Ala-Gln-Ile-His-Phe
-
-
Ac-Leu-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Val-Met-NH2
-
HTLV-I inhibition 83%
Ac-Phe-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Val-Met-NH2
-
HTLV-I inhibition 74%
Ac-Pro-Gln-Ile-Thr-Leu-Trp-Gln-Arg-Pro-NH2
-
-
Ac-Ser-Leu-Asn-Phe-CH(OH)CH2NH-Pro-Ile-Val-methyl ester
Ac-Thr-Val-Ser-Phe-Asn-Phe
-
-
Ac-Val-allophenylnorstatine-Pro-Val-Met-His-OH
-
HTLV-I inhibition below 30%
Ac-Val-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Val-Met-NH2
-
HTLV-I inhibition 77%
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-((2,2-dimethylpropyl)amino)
-
-
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-((2-methylprop-2-en-1-yl)amino)
-
-
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-((2-methylpropyl)amino)
-
-
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-((cyclopropyl)amino)
-
-
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-(2-methylbenzylamino)
-
-
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-(3-iodobenzylamino)
-
-
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-(prop-2-en-1-ylamino)
-
-
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-(propylamino)
-
-
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Gln-NH2
-
-
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Met-NH2
-
-
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-NH2
-
-
acetyl-(L-(+)-alpha-phenylglycine)-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Met-NH2
-
-
acetyl-(L-tert-leucine)-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Met-NH2
-
-
acetyl-Gln-Val-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Val-Met-NH2
-
-
acetyl-Ile-(L-(+)-alpha-phenylglycine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Met-NH2
-
-
acetyl-Ile-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-(L-(+)-alpha-phenylglycine)-Met-NH2
-
-
acetyl-Ile-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-(L-tert-leucine)-Met-NH2
-
-
acetyl-Ile-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Ala-NH2
-
-
acetyl-Ile-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Gln-NH2
-
-
acetyl-Ile-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Met-NH2
-
-
acetyl-Ile-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-NH2
-
-
acetyl-Ile-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Phe-NH2
-
-
acetyl-Ile-Ile-(phenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Met-NH2
-
-
Ala-Pro-Gln-Val-statine-Val-Met-His-Pro
-
-
Gln-Met-Gln-Gly-Val-Leu-Tyr-Leu
-
-
H-allophenylnorstatine-Pro-Val-Met-His-OH
-
HTLV-I inhibition below 30%
H-Gln-Val-allophenylnorstatine-Pro-Val-Met-His-OH
-
HTLV-I inhibition below 30%
H-Ile- NHCH(CH2CH(CH3)2)CH(OH)CH2-Pro-NHCH2C6H5I
-
-
H-Pro-Gln-Val-allophenylnorstatine-(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid-Val-Met-His-OH
-
HTLV-I inhibition 99%
H-Pro-Gln-Val-allophenylnorstatine-Pro-NH2
-
HTLV-I inhibition below 30%
H-Pro-Gln-Val-allophenylnorstatine-Pro-Val-Met-His-OH
-
HTLV-I inhibition 94%
H-Pro-Gln-Val-allophenylnorstatine-Pro-Val-Met-NH2
-
HTLV-I inhibition 86%
H-Pro-Gln-Val-allophenylnorstatine-Pro-Val-NH2
-
HTLV-I inhibition below 30%
H-Pro-Pro-Val-Ile-NHCH(CH2CH(CH3)2)CH(OH)CH2-Pro-NHCH2C6H5I
-
-
H-Pro-Val-Ile-hydroxyethylamine[(R)-isobutyl,(R)-hydroxy]-Pro-NH-CH2-C6H4I
-
-
H-Pro-Val-Ile-hydroxyethylamine[(R)-isobutyl,(S)-hydroxy]-Pro-NH-CH2-C6H4I
-
-
H-Pro-Val-Ile-hydroxyethylamine[(S)-isobutyl,(R)-hydroxy]-Pro-NH-CH2-C6H4I
-
-
H-Pro-Val-Ile-hydroxyethylamine[(S)-isobutyl,(S)-hydroxy]-Pro-NH-CH2-C6H4I
-
-
H-Pro-Val-Ile-NHCH(CH2CH(CH3)2)CH(OH)CH2-Pro-Ile-NHCH2C6H5I
-
-
H-Pro-Val-Ile-NHCH(CH2CH(CH3)2)CH(OH)CH2-Pro-NHCH2C6H5I
-
-
H-Val-allophenylnorstatine-Pro-Val-Met-His-OH
-
HTLV-I inhibition below 30%
H-Val-Ile-NHCH(CH2CH(CH3)2)CH(OH)CH2-Pro-Ile-NHCH2C6H5I
-
-
H-Val-Ile-NHCH(CH2CH(CH3)2)CH(OH)CH2-Pro-NHCH2C6H5I
-
-
isobutyl oxycarbonyl-Lys--Val-Val-(3S,4S)-statine-Ala-isoamylamine
-
i.e. CS-I-27
isovaleryl-Lys-Val-(3S,4S)-statine-Ala-isoamylamine
-
i.e. CS-I-25
isovaleryl-Val-Nle-(3S,4S)-statine-Ala-isoamylamine
-
i.e. CS-I-22
isovaleryl-Val-Val-(3S,4S)-statine-Ala-Lys-methyl ester
-
i.e. CS-I-52
isovaleryl-Val-Val-(3S,4S)-statine-Lys-isoamylamine
-
i.e. CS-I-51
KNI-10220
-
HTLV-1 PR-specific inhibitor, 61% inhibition at 50 nM
KNI-10296c
-
HTLV-1 PR-specific inhibitor, 28% inhibition at 50 nM
KNI-10516
-
HTLV-1 PR-specific inhibitor, 86% inhibition at 50 nM
KNI-10562
-
78% inhibition at 50 nM
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(4-amino-N-benzylbenzenesulfonamide)
-
-
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(N-benzyl-2-chlorobenzenesulfonamide)
-
-
-
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(N-benzyl-2-methylbenzenesulfonamide)
-
-
-
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(N-benzyl-4-nitrobenzenesulfonamide)
-
-
-
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(N-benzylbenzenesulfonamide)
-
-
-
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis[N-(2-methylprop-2-en-1-yl)benzenesulfonamide]
-
-
-
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis[N-(3-methylbut-2-en-1-yl)benzenesulfonamide]
-
-
-
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis[N-(4-iodobenzyl)benzenesulfonamide]
-
-
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis[N-(prop-2-en-1-yl)benzenesulfonamide]
-
-
-
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis[N-[4-(trifluoromethyl)benzyl]benzenesulfonamide]
-
-
-
N-(3-[[(benzylsulfamoyl)carbonyl]amino]-1-cyclopentylpropyl)-N-carbamoyl-N2-hydroxy-N2-(hydroxymethyl)glycinamide
-
N-[(2R)-2-[(1R)-2-[(2R)-1-(benzylcarbamoyl)pyrrolidin-2-yl]-1-hydroxyethyl]-4-methylpentanoyl]-D-isoleucyl-D-valyl-D-prolyl-D-prolinamide
-
-
N-[(2R)-2-[(1S)-2-[(2R)-1-(benzylcarbamoyl)pyrrolidin-2-yl]-1-hydroxyethyl]-4-methylpentanoyl]-D-isoleucyl-D-valyl-D-prolyl-D-prolinamide
-
-
N-[(2S)-2-[(1R)-2-[(2R)-1-(benzylcarbamoyl)pyrrolidin-2-yl]-1-hydroxyethyl]-4-methylpentanoyl]-D-isoleucyl-D-valyl-D-prolyl-D-prolinamide
-
-
N-[(2S)-2-[(1S)-2-[(2R)-1-(benzylcarbamoyl)pyrrolidin-2-yl]-1-hydroxyethyl]-4-methylpentanoyl]-D-isoleucyl-D-valyl-D-prolyl-D-prolinamide
-
-
N-[(2S)-4-[(4R)-4-[(2,2-dimethylpropyl)carbamoyl]-5,5-dimethyl-1,3-thiazolidin-3-yl]-4-oxo-1-phenylbutan-2-yl]-N2-[(2S)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]-3-methyl-L-valinamide
-
-
N-[(2S)-4-[(4R)-4-[(2-tert-butylhydrazinyl)carbonyl]-5,5-dimethyl-1,3-thiazolidin-3-yl]-4-oxo-1-phenylbutan-2-yl]-N2-[(2S)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]-3-methyl-L-valinamide
-
-
N-[(2S,3R)-3-(acetylamino)-2-hydroxy-5-methylhexyl]-D-isoleucyl-D-valyl-D-prolinamide
-
-
N-[(2S,3R)-3-[(1-acetyl-D-prolyl)amino]-2-hydroxy-5-methylhexyl]-D-isoleucyl-D-valyl-D-prolinamide
-
-
N2-[(2S)-2-(b-alanylamino)-2-phenylacetyl]-N-[(2S)-4-[(4R)-4-[(2,2-dimethylpropyl)carbamoyl]-5,5-dimethyl-1,3-thiazolidin-3-yl]-4-oxo-1-phenylbutan-2-yl]-3-methyl-L-valinamide
-
-
N2-[(2S)-2-(butanoylamino)-2-phenylacetyl]-N-[(2S)-4-[(4R)-4-[(2,2-dimethylpropyl)carbamoyl]-5,5-dimethyl-1,3-thiazolidin-3-yl]-4-oxo-1-phenylbutan-2-yl]-3-methyl-L-valinamide
-
-
N2-[(2S)-2-amino-2-(2,4,6-trifluorophenyl)ethyl]-N-[(2S)-4-[(4R)-4-[(2,2-dimethylpropyl)carbamoyl]-5,5-dimethyl-1,3-thiazolidin-3-yl]-4-oxo-1-phenylbutan-2-yl]-3-methyl-L-valinamide
-
-
phenyl (9S)-5-cyclopentyl-3,6,9-trihydroxy-2-(naphthalen-2-yl)-2,5,8,10-tetraazadodecane-12-sulfonate
-
-
Pro-Gln-Val-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Val-Met-His-Pro
-
-
Pro-Gln-Val-allophenylnorstatine-Pro-Val-Met-His-Pro
-
-
Pro-Gln-Val-[(4S,3S)-4-amino-3-hydroxy-6-methylheptanoic acid]-Ala-Leu
-
-
Pro-Val-Ile-Pro-Leu-Asp-Pro-Ala-Arg-Arg-Pro-Val
-
-
purvalanol-A
-
shows interactions with both chain A Gly34 and chain B Asp32 and Gly34 amino acid residues of the wild-type enzyme. Purvalanol A shows week interactions with the mutant HTLV-1 PR
tert-butyloxycarbonyl-Val-Val-Phe-Psi[P(O)(OH)]-Phe-Val-Val-NH2
-
-
tetradecahydrophenazine-2,3-diamine
-
inhibitory to both protease and HTLV-1 infected cells
Tyr-Leu-Pro-Glu-Ala-Lys-Arg-Pro-Pro-Val-Ile-Leu
-
-
2-(4-tert-butylphenyl)-N-carbamoyl-N-[3-[([[(3,5-dichloro-4-oxopyridin-1(4H)-yl)methyl]sulfamoyl]carbonyl)amino]-3-[3-(hydroxyamino)-4-oxopyrrolidin-1-yl]propyl]acetamide
-
strong inhibition, enzyme-bound structure modelling and molecular dynamics
-
2-(4-tert-butylphenyl)-N-carbamoyl-N-[3-[([[(3,5-dichloro-4-oxopyridin-1(4H)-yl)methyl]sulfamoyl]carbonyl)amino]-3-[3-(hydroxyamino)-4-oxopyrrolidin-1-yl]propyl]acetamide
-
-
-
Ac-Ser-Leu-Asn-Phe-CH(OH)CH2NH-Pro-Ile-Val-methyl ester
-
i.e. JG-365
Ac-Ser-Leu-Asn-Phe-CH(OH)CH2NH-Pro-Ile-Val-methyl ester
-
-
KNI-10673
-
29% inhibition at 50 nM
KNI-10681
-
HTLV-1 PR-specific inhibitor, 40% inhibition at 50 nM
KNI-10683
-
HTLV-1 PR-specific inhibitor, 76% inhibition at 50 nM
KNI-10729
-
HTLV-1 PR-specific inhibitor, 79% inhibition at 50 nM
KNI-1595b
-
HTLV-1 PR-specific inhibitor, 5% inhibition at 50 nM
N-(3-[[(benzylsulfamoyl)carbonyl]amino]-1-cyclopentylpropyl)-N-carbamoyl-N2-hydroxy-N2-(hydroxymethyl)glycinamide
-
strong inhibition, enzyme-bound structure modelling and molecular dynamics
-
N-(3-[[(benzylsulfamoyl)carbonyl]amino]-1-cyclopentylpropyl)-N-carbamoyl-N2-hydroxy-N2-(hydroxymethyl)glycinamide
-
-
-
additional information
-
currently employed HIV protease inhibitors can not be used to treat HTLV infections
-
additional information
-
several inhibitors of HIV-1 or other retrovitral proteinases are tested on HTLV-1 proteinase, only two inhibit with a Ki-value lower than 100 nM
-
additional information
-
the HIV type 1 protease inhibitors indinavir, saquinavir, ritonavir, or nelfinavir fail to block processing of HTLV-1 Gag
-
additional information
-
Ac-Thr-Ile-Nle(reduced peptide bond)-Nle-Gln-Arg; Arg-Val-Leu(reduced peptide bond)-Phe-Glu-Ala-Nle-NH2; Ser-Gln-Asn-Phe(reduced peptide bond)-Pro-Ile-Val
-
additional information
-
results show that a tetrapeptide sequence is necessary to achieve potent inhibition
-
additional information
design of inhibitory compounds that circumvent the dominant residue Met37 in the binding pocket
-
additional information
-
design of inhibitory compounds that circumvent the dominant residue Met37 in the binding pocket
-
additional information
-
structure-function relationships and binding mode analysis, detailed overview. Comparisons with HIV protease
-
additional information
-
inhibitor design and evaluation of 15 inhibitory compounds based on the conformations of a class of HIV-1 aspartyl protease inhibitor sulfonamid-peptoid, molecular docking study and molecular dynamics simulations, hydrogen bond patterns, overview. The addition of two cyclic hydrocarbons to both ends of sulfonamide peptoids leads to the formation of new hydrophobic interactions due to the semi-circular form of these compounds, connecting the first chain of protease to the two ends of tested ligands via hydrophobic interactions. The strongest H-bond interaction has occurs between 2-(4-tert-butylphenyl)-N-carbamoyl-N-[3-[([[(3,5-dichloro-4-oxopyridin-1(4H)-yl)methyl]sulfamoyl]carbonyl)amino]-3-[3-(hydroxyamino)-4-oxopyrrolidin-1-yl]propyl]acetamide and N-(3-[[(benzylsulfamoyl)carbonyl]amino]-1-cyclopentylpropyl)-N-carbamoyl-N2-hydroxy-N2-(hydroxymethyl)glycinamide inhibitors with both S3 and S4 subsite in first chain of HTLV-1 protease
-
additional information
-
inhibitor library screening, free energy calculation, molecular docking, and molecular dynamics simulations, molecular modelling using the crystal structure of HTLV-1 PR (PDB ID 2B7F), overview. Molecular recognition and interaction analysis. HIV protease drugs fail to inhibit HTLV-1 infections. The active site region is expanded in HTLV-1 protease, and the known HIV protease drugs cannot sustain the inhibitory profile against the HTLV-1 PR
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0000804
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-(2,2-dimethyl)butanoylamino-2-phenyl]acetylamino-3,3-dimethyl)-butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
Human T-cell leukemia virus type I
-
assay performed with mutant L40I
0.0000842
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-(2-methyl)pentanoylamino-2-phenyl]acetylamino-3,3-dimethyl)- butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
Human T-cell leukemia virus type I
-
assay performed with mutant L40I
0.0000833
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-(3,3-dimethyl)butanoylamino-2-phenyl]acetylamino-3,3-dimethyl)-butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
Human T-cell leukemia virus type I
-
assay performed with mutant L40I
0.0001017
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-(3-methyl)butanoylamino-2-phenyl]acetylamino-3,3-dimethyl)-butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
Human T-cell leukemia virus type I
-
assay performed with mutant L40I
0.0000882
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-(3-methyl)pentanoylamino-2-phenyl]acetylamino-3,3-dimethyl)butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
Human T-cell leukemia virus type I
-
assay performed with mutant L40I
0.0001048
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-(3-phenyl)-propanoylamino-2-phenyl]acetylamino-3,3-dimethyl)butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
Human T-cell leukemia virus type I
-
assay performed with mutant L40I
0.0000965
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-(4-methyl)pentanoylamino-2-phenyl]acetylamino-3,3-dimethyl) butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
Human T-cell leukemia virus type I
-
assay performed with mutant L40I
0.000107
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-acetylamino-2-phenyl]acetylamino-3,3-dimethyl)butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
Human T-cell leukemia virus type I
-
assay performed with mutant L40I
0.000331
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-amino-2-phenyl]acetylamino-3,3-dimethyl)butanoylamino-2-hydroxy-4-phenylbutanoyl))-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
Human T-cell leukemia virus type I
-
assay performed with mutant L40I
0.0000792
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-benzoylamino-2-phenyl]acetylamino-3,3-dimethyl)butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
Human T-cell leukemia virus type I
-
assay performed with mutant L40I
0.0000982
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-cyclohexanecarbonylamino-2-phenyl]acetylamino-3,3-dimethyl)-butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
Human T-cell leukemia virus type I
-
assay performed with mutant L40I
0.0000935
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-isobutyrylamino-2-phenyl]acetylamino-3,3-dimethyl)butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
Human T-cell leukemia virus type I
-
assay performed with mutant L40I
0.000092
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-pentanoylamino-2-phenyl]acetylamino-3,3-dimethyl)butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
Human T-cell leukemia virus type I
-
assay performed with mutant L40I
0.0001045
(R)-N-isobutyl-3-(((2S,3S)-3-((2S)-2-[(2S)-2-propionylamino-2-phenyl]acetylamino-3,3-dimethyl)butanoylamino-2-hydroxy-4-phenyl))butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
Human T-cell leukemia virus type I
-
assay performed with mutant L40I
0.0001043
(R)-N-isobutyl-3-[[(2S,3S)-3-[(2S)-2-[(2S)-2-butyrylamino-2-phenyl]acetylamino-3,3-dimethyl]butanoylamino-2-hydroxy-4-phenyl]]butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
Human T-cell leukemia virus type I
-
assay performed with mutant L40I
0.0000969
(R)-N-isobutyl-3-[[(2S,3S)-3-[(2S)-2-[(2S)-2-cyclopropanecarbonylamino-2-phenyl]acetylamino-3,3-dimethyl]butanoylamino-2-hydroxy-4-phenyl]]butanoyl-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
Human T-cell leukemia virus type I
-
assay performed with mutant L40I
0.000113
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-((2,2-dimethylpropyl)amino)
Human T-cell leukemia virus type I
-
-
0.00014
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-((2-methylprop-2-en-1-yl)amino)
Human T-cell leukemia virus type I
-
-
0.000107
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-((2-methylpropyl)amino)
Human T-cell leukemia virus type I
-
-
0.000146
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-((cyclopropyl)amino)
Human T-cell leukemia virus type I
-
-
0.000103
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-(2-methylbenzylamino)
Human T-cell leukemia virus type I
-
-
0.000473
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-(3-iodobenzylamino)
Human T-cell leukemia virus type I
-
-
0.000131
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-(prop-2-en-1-ylamino)
Human T-cell leukemia virus type I
-
-
0.000193
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-(propylamino)
Human T-cell leukemia virus type I
-
-
0.000084
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Gln-NH2
Human T-cell leukemia virus type I
-
-
0.000101
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Met-NH2
Human T-cell leukemia virus type I
-
-
0.000144
acetyl-(L-(+)-alpha-phenylglycine)-(L-tert-leucine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-NH2
Human T-cell leukemia virus type I
-
-
0.000102
acetyl-(L-(+)-alpha-phenylglycine)-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Met-NH2
Human T-cell leukemia virus type I
-
-
0.000201
acetyl-(L-tert-leucine)-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Met-NH2
Human T-cell leukemia virus type I
-
-
0.000353
acetyl-Gln-Val-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Val-Met-NH2
Human T-cell leukemia virus type I
-
-
0.000145 - 0.00032
acetyl-Ile-(L-(+)-alpha-phenylglycine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Met-NH2
0.000123
acetyl-Ile-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-(L-(+)-alpha-phenylglycine)-Met-NH2
Human T-cell leukemia virus type I
-
-
0.00018
acetyl-Ile-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-(L-tert-leucine)-Met-NH2
Human T-cell leukemia virus type I
-
-
0.00016
acetyl-Ile-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Ala-NH2
Human T-cell leukemia virus type I
-
-
0.000159
acetyl-Ile-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Gln-NH2
Human T-cell leukemia virus type I
-
-
0.000088
acetyl-Ile-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Met-NH2
Human T-cell leukemia virus type I
-
-
0.000249
acetyl-Ile-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-NH2
Human T-cell leukemia virus type I
-
-
0.000095
acetyl-Ile-Ile-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Phe-NH2
Human T-cell leukemia virus type I
-
-
0.00018
acetyl-Ile-Ile-(phenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Met-NH2
Human T-cell leukemia virus type I
-
-
0.0024
H-Pro-Pro-Val-Ile-NHCH(CH2CH(CH3)2)CH(OH)CH2-Pro-NHCH2C6H5I
Human T-cell leukemia virus type I
-
-
0.00013
H-Pro-Val-Ile-NHCH(CH2CH(CH3)2)CH(OH)CH2-Pro-Ile-NHCH2C6H5I
Human T-cell leukemia virus type I
-
-
0.0058
H-Pro-Val-Ile-NHCH(CH2CH(CH3)2)CH(OH)CH2-Pro-NHCH2C6H5I
Human T-cell leukemia virus type I
-
-
0.0183
H-Val-Ile-NHCH(CH2CH(CH3)2)CH(OH)CH2-Pro-Ile-NHCH2C6H5I
Human T-cell leukemia virus type I
-
-
0.0196
H-Val-Ile-NHCH(CH2CH(CH3)2)CH(OH)CH2-Pro-NHCH2C6H5I
Human T-cell leukemia virus type I
-
-
0.000015
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(4-amino-N-benzylbenzenesulfonamide)
Human T-cell leukemia virus type I
-
pH and temperature not specified in the publication
0.0024
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(N-benzyl-2-chlorobenzenesulfonamide)
Human T-cell leukemia virus type I
-
pH and temperature not specified in the publication
-
0.0026
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(N-benzyl-2-methylbenzenesulfonamide)
Human T-cell leukemia virus type I
-
pH and temperature not specified in the publication
-
0.0079
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(N-benzyl-4-nitrobenzenesulfonamide)
Human T-cell leukemia virus type I
-
pH and temperature not specified in the publication
-
0.002
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(N-benzylbenzenesulfonamide)
Human T-cell leukemia virus type I
-
pH and temperature not specified in the publication
-
0.0178
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis[N-(2-methylprop-2-en-1-yl)benzenesulfonamide]
Human T-cell leukemia virus type I
-
pH and temperature not specified in the publication
-
0.0116
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis[N-(3-methylbut-2-en-1-yl)benzenesulfonamide]
Human T-cell leukemia virus type I
-
pH and temperature not specified in the publication
-
0.2
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis[N-(4-iodobenzyl)benzenesulfonamide]
Human T-cell leukemia virus type I
-
pH and temperature not specified in the publication
0.1725
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis[N-(prop-2-en-1-yl)benzenesulfonamide]
Human T-cell leukemia virus type I
-
pH and temperature not specified in the publication
-
0.25
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis[N-[4-(trifluoromethyl)benzyl]benzenesulfonamide]
Human T-cell leukemia virus type I
-
pH and temperature not specified in the publication
-
0.35
N-[(2R)-2-[(1R)-2-[(2R)-1-(benzylcarbamoyl)pyrrolidin-2-yl]-1-hydroxyethyl]-4-methylpentanoyl]-D-isoleucyl-D-valyl-D-prolyl-D-prolinamide
Human T-cell leukemia virus type I
-
in 0.5 M sodium acetate buffer, pH 5.6, containing 10% (v/v) glycerol, 10 mM dithiothretiol and 4 M NaCl, temperature not specified in the publication
1.5
N-[(2R)-2-[(1S)-2-[(2R)-1-(benzylcarbamoyl)pyrrolidin-2-yl]-1-hydroxyethyl]-4-methylpentanoyl]-D-isoleucyl-D-valyl-D-prolyl-D-prolinamide
Human T-cell leukemia virus type I
-
in 0.5 M sodium acetate buffer, pH 5.6, containing 10% (v/v) glycerol, 10 mM dithiothretiol and 4 M NaCl, temperature not specified in the publication
0.16
N-[(2S)-2-[(1R)-2-[(2R)-1-(benzylcarbamoyl)pyrrolidin-2-yl]-1-hydroxyethyl]-4-methylpentanoyl]-D-isoleucyl-D-valyl-D-prolyl-D-prolinamide
Human T-cell leukemia virus type I
-
in 0.5 M sodium acetate buffer, pH 5.6, containing 10% (v/v) glycerol, 10 mM dithiothretiol and 4 M NaCl, temperature not specified in the publication
0.55
N-[(2S)-2-[(1S)-2-[(2R)-1-(benzylcarbamoyl)pyrrolidin-2-yl]-1-hydroxyethyl]-4-methylpentanoyl]-D-isoleucyl-D-valyl-D-prolyl-D-prolinamide
Human T-cell leukemia virus type I
-
in 0.5 M sodium acetate buffer, pH 5.6, containing 10% (v/v) glycerol, 10 mM dithiothretiol and 4 M NaCl, temperature not specified in the publication
0.0000072
N-[(2S)-4-[(4R)-4-[(2,2-dimethylpropyl)carbamoyl]-5,5-dimethyl-1,3-thiazolidin-3-yl]-4-oxo-1-phenylbutan-2-yl]-N2-[(2S)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]-3-methyl-L-valinamide
Human T-cell leukemia virus type I
-
recombinant protease mutant L40I, pH not specified in the publication, temperature not specified in the publication
0.0000104
N-[(2S)-4-[(4R)-4-[(2-tert-butylhydrazinyl)carbonyl]-5,5-dimethyl-1,3-thiazolidin-3-yl]-4-oxo-1-phenylbutan-2-yl]-N2-[(2S)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]-3-methyl-L-valinamide
Human T-cell leukemia virus type I
-
recombinant protease mutant L40I, pH not specified in the publication, temperature not specified in the publication
10
N-[(2S,3R)-3-(acetylamino)-2-hydroxy-5-methylhexyl]-D-isoleucyl-D-valyl-D-prolinamide
Human T-cell leukemia virus type I
-
IC50 above 10 mM, in 0.5 M sodium acetate buffer, pH 5.6, containing 10% (v/v) glycerol, 10 mM dithiothretiol and 4 M NaCl, temperature not specified in the publication
10
N-[(2S,3R)-3-[(1-acetyl-D-prolyl)amino]-2-hydroxy-5-methylhexyl]-D-isoleucyl-D-valyl-D-prolinamide
Human T-cell leukemia virus type I
-
IC50 above 10 mM, in 0.5 M sodium acetate buffer, pH 5.6, containing 10% (v/v) glycerol, 10 mM dithiothretiol and 4 M NaCl, temperature not specified in the publication
0.0000057
N2-[(2S)-2-(b-alanylamino)-2-phenylacetyl]-N-[(2S)-4-[(4R)-4-[(2,2-dimethylpropyl)carbamoyl]-5,5-dimethyl-1,3-thiazolidin-3-yl]-4-oxo-1-phenylbutan-2-yl]-3-methyl-L-valinamide
Human T-cell leukemia virus type I
-
recombinant protease mutant L40I, pH not specified in the publication, temperature not specified in the publication
0.0000064
N2-[(2S)-2-(butanoylamino)-2-phenylacetyl]-N-[(2S)-4-[(4R)-4-[(2,2-dimethylpropyl)carbamoyl]-5,5-dimethyl-1,3-thiazolidin-3-yl]-4-oxo-1-phenylbutan-2-yl]-3-methyl-L-valinamide
Human T-cell leukemia virus type I
-
recombinant protease mutant L40I, pH not specified in the publication, temperature not specified in the publication
0.000013
N2-[(2S)-2-amino-2-(2,4,6-trifluorophenyl)ethyl]-N-[(2S)-4-[(4R)-4-[(2,2-dimethylpropyl)carbamoyl]-5,5-dimethyl-1,3-thiazolidin-3-yl]-4-oxo-1-phenylbutan-2-yl]-3-methyl-L-valinamide
Human T-cell leukemia virus type I
-
pH 5.6, 37°C
0.000152
Pro-Gln-Val-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Val-Met-His-Pro
Human T-cell leukemia virus type I
-
-
0.000159
Pro-Gln-Val-allophenylnorstatine-Pro-Val-Met-His-Pro
Human T-cell leukemia virus type I
-
-
0.000145
acetyl-Ile-(L-(+)-alpha-phenylglycine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Met-NH2
Human T-cell leukemia virus type I
-
-
0.00032
acetyl-Ile-(L-(+)-alpha-phenylglycine)-(allophenylnorstatine)-[(R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid]-Ile-Met-NH2
Human T-cell leukemia virus type I
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Malik K.T.A.; Even J.; Karpas A.
Molecular cloning and complete nucleotide sequence of an adult T cell leukaemia virus/human T cell leukaemia virus type I (ATLV/HTLV-I) isolate of Caribbean origin: relationship to other members of the ATLV/HTLV-I subgroup
J. Gen. Virol.
69
1695-1710
1988
Human T-cell leukemia virus type I
-
brenda
Kobayashi, M.; Ohi, Y.; Asano, T.; Hayakawa, T.; Kato, K.; Kakinuma, A.; Hatanaka, M.
Purification and characterization of human T-cell leukemia virus type I protease produced in Escherichia coli
FEBS Lett.
293
106-110
1991
Human T-cell leukemia virus type I
brenda
Llido, S.; Langlois d'Estaintot, B.; Dautant, A.; Geoffre, S.; Picard, P.; Precigoux, G.
Conformational study of a putative HTLV-1 retroviral protease inhibitor
Acta Crystallogr. Sect. D
49
344-348
1993
Human T-cell leukemia virus type I
brenda
Ding, Y.S.; Rich, D.H.; Ikeda, R.A.
Substrates and inhibitors of human T-cell leukemia virus type I protease
Biochemistry
37
17514-17518
1998
Human T-cell leukemia virus type I
brenda
Hayakawa, T.; Misumi, Y.; Kobayashi, M.; Yamamoto, Y.; Fujisawa, Y.
Requirement of N- and C-terminal regions for enzymatic activity of human T-cell leukemia virus type I protease
Eur. J. Biochem.
206
919-925
1992
Human T-cell leukemia virus type I
brenda
Akaji, K.; Teruya, K.; Aimoto, S.
Solid-Phase Synthesis of HTLV-1 Protease Inhibitors Containing Hydroxyethylamine Dipeptide Isostere
J. Org. Chem.
68
4755-4763
2003
Human T-cell leukemia virus type I
brenda
Tzser, J.; Zahuczky, G.; Bagossi, P.; Louis, J.M.; Copeland, T.D.; Oroszlan, S.; Harrison, R.W.; Weber, I.T.
Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases
Eur. J. Biochem.
267
6287-6295
2000
Human T-cell leukemia virus type I
brenda
Davis, D.A.; Brown, C.A.; Newcomb, F.M.; Boja, E.S.; Fales, H.M.; Kaufman, J.; Stahl, S.J.; Wingfield, P.; Yarchoan, R.
Reversible oxidative modification as a mechanism for regulating retroviral protease dimerization and activation
J. Virol.
77
3319-3325
2003
Human T-cell leukemia virus type I
brenda
Louis, J.M.; Oroszlan, S.; Tozser, J.
Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase
J. Biol. Chem.
274
6660-6666
1999
Human T-cell leukemia virus type I
brenda
Saiga, A.; Tanaka, T.; Orita, S.; Sato, A.; Sato, S.; Hachisu, T.; Abe, K.; Kimura, Y.; Kondo, Y.; Fujiwara, T.; et al.
Human T-cell leukemia virus type 1 protease protein expressed in Escherichia coli possesses aspartic proteinase activity
Arch. Virol.
128
195-210
1993
Human T-cell leukemia virus type I
brenda
Ding, Y.S.; Owen, S.M.; Lal, R.B.; Ikeda, R.A.
Efficient expression and rapid purification of human T-cell leukemia virus type 1 protease
J. Virol.
72
3383-3386
1998
Human T-cell leukemia virus type I
brenda
Pettit, S.C.; Sanchez, R.; Smith, T.; Wehbie, R.; Derse, D.; Swanstrom, R.
HIV type 1 protease inhibitors fail to inhibit HTLV-I Gag processing in infected cells
AIDS Res. Hum. Retroviruses
14
1007-1014
1998
Human T-cell leukemia virus type I
brenda
Mariani, V.L.; Shuker, S.B.
Identification of the RT-RH/IN cleavage site of HTLV-I
Biochem. Biophys. Res. Commun.
300
268-270
2003
Human T-cell leukemia virus type I
brenda
Ha, J.J.; Gaul, D.A.; Mariani, V.L.; Ding, Y.S.; Ikeda, R.A.; Shuker, S.B.
HTLV-I protease cleavage of P19/24 substrates is not dependent on NaCl concentration
Bioorg. Chem.
30
138-144
2002
Human T-cell leukemia virus type I
brenda
Shuker, S.B.; Mariani, V.L.; Herger, B.E.; Dennison, K.J.
Understanding HTLV-I Protease
Chem. Biol.
10
373-380
2003
Human T-cell leukemia virus type I
brenda
Bagossi, P.; Sperka, T.; Feher, A.; Kadas, J.; Zahuczky, G.; Miklossy, G.; Boross, P.; Toezser, J.
Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites
J. Virol.
79
4213-4218
2005
Human T-cell leukemia virus type I
brenda
Herger, B.E.; Mariani, V.L.; Dennison, K.; Shuker, S.B.
The 10 C-terminal residues of HTLV-I protease are not necessary for enzymatic activity
Biochem. Biophys. Res. Commun.
320
1306-1308
2004
Human T-cell leukemia virus type I
brenda
Alvarez, E.; Castello, A.; Menendez-Arias, L.; Carrasco, L.
HIV protease cleaves poly(A)-binding protein
Biochem. J.
396
219-226
2006
Human T-cell leukemia virus type I
brenda
Kadas, J.; Weber, I.T.; Bagossi, P.; Miklossy, G.; Boross, P.; Oroszlan, S.; Toezser, J.
Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease
J. Biol. Chem.
279
27148-27157
2004
Human T-cell leukemia virus type I
brenda
Li, M.; Laco, G.S.; Jaskolski, M.; Rozycki, J.; Alexandratos, J.; Wlodawer, A.; Gustchina, A.
Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design
Proc. Natl. Acad. Sci. USA
102
18332-18337
2005
Human T-cell leukemia virus type I
brenda
Zhang, M.; Nguyen, J.T.; Kumada, H.O.; Kimura, T.; Cheng, M.; Hayashi, Y.; Kiso, Y.
Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P(3)-cap moieties
Bioorg. Med. Chem.
16
5795-5802
2008
Human T-cell leukemia virus type I
brenda
Naka, H.; Teruya, K.; Bang, J.K.; Aimoto, S.; Tatsumi, T.; Konno, H.; Nosaka, K.; Akaji, K.
Evaluations of substrate specificity and inhibition at PR/p3 cleavage site of HTLV-1 protease
Bioorg. Med. Chem. Lett.
16
3761-3764
2006
Human T-cell leukemia virus type I
brenda
Kimura, T.; Nguyen, J.T.; Maegawa, H.; Nishiyama, K.; Arii, Y.; Matsui, Y.; Hayashi, Y.; Kiso, Y.
Chipping at large, potent human T-cell leukemia virus type 1 protease inhibitors to uncover smaller, equipotent inhibitors
Bioorg. Med. Chem. Lett.
17
3276-3280
2007
Human T-cell leukemia virus type I
brenda
Nguyen, J.T.; Zhang, M.; Kumada, H.O.; Itami, A.; Nishiyama, K.; Kimura, T.; Cheng, M.; Hayashi, Y.; Kiso, Y.
Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors
Bioorg. Med. Chem. Lett.
18
366-370
2008
Human T-cell leukemia virus type I
brenda
Tatsumi, T.; Awahara, C.; Naka, H.; Aimoto, S.; Konno, H.; Nosaka, K.; Akaji, K.
Evaluation of retro-inverso modifications of HTLV-1 protease inhibitors containing a hydroxyethylamine isoster
Bioorg. Med. Chem.
18
2720-2727
2010
Human T-cell leukemia virus type I
brenda
Satoh, T.; Li, M.; Nguyen, J.T.; Kiso, Y.; Gustchina, A.; Wlodawer, A.
Crystal structures of inhibitor complexes of human T-cell leukemia virus (HTLV-1) protease
J. Mol. Biol.
401
626-641
2010
Human T-cell leukemia virus type I
brenda
Nguyen, J.; Kato, K.; Kumada, H.; Hidaka, K.; Kimura, T.; Kiso, Y.
Maintaining potent HTLV-I protease inhibition without the P3-cap moiety in small tetrapeptidic inhibitors
Bioorg. Med. Chem. Lett.
21
1832-1837
2011
Human T-cell leukemia virus type I
brenda
Nguyen, J.T.; Kato, K.; Hidaka, K.; Kumada, H.O.; Kimura, T.; Kiso, Y.
Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles
Bioorg. Med. Chem. Lett.
21
2425-2429
2011
Human T-cell leukemia virus type I
brenda
Li, C.; Li, X.; Lu, W.
Total chemical synthesis of human T-cell leukemia virus type 1 protease via native chemical ligation
Biopolymers
94
487-494
2010
Human T-cell leukemia virus type I
brenda
Rcker, P.; Horn, A.; Meiselbach, H.; Sticht, H.
A comparative study of HIV-1 and HTLV-I protease structure and dynamics reveals a conserved residue interaction network
J. Mol. Model.
17
2693-2705
2011
Human T-cell leukemia virus type I (P03362), Human T-cell leukemia virus type I, Human T-cell leukemia virus type I Japan ATK-1 subtype A (P03362)
brenda
Kumada, H.O.; Nguyen, J.T.; Kakizawa, T.; Hidaka, K.; Kimura, T.; Hayashi, Y.; Kiso, Y.
Development of [Ile40]HTLV-I protease inhibition assay using novel fluorogenic and chromogenic substrate
J. Pept. Sci.
17
569-575
2011
Human T-cell leukemia virus type I
brenda
Demir, A.; Oguariri, R.M.; Magis, A.; Ostrov, D.A.; Imamichi, T.; Dunn, B.M.
Kinetic characterization of newly discovered inhibitors of various constructs of human T-cell leukemia virus-1 (HTLV-1) protease and their effect on HTLV-1-infected cells
Antivir. Ther.
17
883-892
2012
Human T-cell leukemia virus type I
brenda
Ma, S.; Vogt, K.; Petrillo, N.; Ruhoff, A.
Characterizing the protonation states of the catalytic residues in apo and substrate-bound human T-cell leukemia virus type 1 protease
Comput. Biol. Chem.
56
61-70
2015
Human T-cell leukemia virus type I (Q82134), Human T-cell leukemia virus type I
brenda
Selvaraj, C.; Singh, P.; Singh, S.K.
Molecular insights on analogs of HIV PR inhibitors toward HTLV-1 PR through QM/MM interactions and molecular dynamics studies: comparative structure analysis of wild and mutant HTLV-1 PR
J. Mol. Recognit.
27
696-706
2014
Human T-cell leukemia virus type I (P03362), Human T-cell leukemia virus type I
brenda
Kuhnert, M.; Blum, A.; Steuber, H.; Diederich, W.E.
Privileged structures meet human T-cell leukemia virus-1 (HTLV-1) C2-symmetric 3,4-disubstituted pyrrolidines as nonpeptidic HTLV-1 protease inhibitors
J. Med. Chem.
58
4845-4850
2015
Human T-cell leukemia virus type I
brenda
Kheirabadi, M.; Maleki, J.; Soufian, S.; Hosseini, S.
Design of new potent HTLV-1 protease inhibitors in silico study
Mol. Biol. Res. Commun.
5
19-30
2016
Human T-cell leukemia virus type I
brenda
Selvaraj, C.; Omer, A.; Singh, P.; Singh, S.
Molecular insights of protein contour recognition with ligand pharmacophoric sites through combinatorial library design and MD simulation in validating HTLV-1 PR inhibitors
Mol. Biosyst.
11
178-189
2015
Human T-cell leukemia virus type I
brenda